AVLN (Avalyn Pharma) ROC (Joel Greenblatt) %: -7,557.28% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AVLN Avalyn Pharma Inc AVLN
11 GF Score
Price $28.50
View Full Analysis

What is Avalyn Pharma ROC (Joel Greenblatt) %?

Avalyn Pharma AVLN -1.01% 11 ROC (Joel Greenblatt) % is -7,557.28% as of Dec. 2025. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,322 Biotechnology companies, Avalyn Pharma ranks worse than 88.35% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Avalyn Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -7,557.28%.

The historical rank and industry rank for Avalyn Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:

AVLN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -60767.02   Med: -34162.15   Max: -7557.28
Current: -7557.28

During the past 2 years, Avalyn Pharma's highest ROC (Joel Greenblatt) % was -7557.28%. The lowest was -60767.02%. And the median was -34162.15%.

AVLN's ROC (Joel Greenblatt) % is ranked worse than
88.35% of 1322 companies
in the Biotechnology industry
Industry Median: -291.605 vs AVLN: -7557.28

Avalyn Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Avalyn Pharma  (NAS:AVLN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Avalyn Pharma ROC (Joel Greenblatt) % Related Terms


Avalyn Pharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Avalyn Pharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avalyn Pharma ROC (Joel Greenblatt) % Chart

Avalyn Pharma Annual Data
Trend Dec24 Dec25
ROC (Joel Greenblatt) %
-60,767.02 -7,557.28

Avalyn Pharma Semi-Annual Data
Dec24 Dec25
ROC (Joel Greenblatt) % -60,767.02 -7,557.28

AVLN vs TRAX, IMTX, ARDX: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Avalyn Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avalyn Pharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalyn Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Avalyn Pharma's ROC (Joel Greenblatt) % falls into.


AVLN
11GF Score
Avalyn Pharma Inc AVLN
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avalyn Pharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.17) - (5.993 + 0 + 2.751)
=-5.574

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 4.664) - (9.355 + 0 + 4.292)
=-8.983

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Avalyn Pharma for the quarter that ended in Dec. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-91.292/( ( (0.094 + max(-5.574, 0)) + (2.322 + max(-8.983, 0)) )/ 2 )
=-91.292/( ( 0.094 + 2.322 )/ 2 )
=-91.292/1.208
=-7,557.28 %

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -7,557.28% mean?
Avalyn Pharma (AVLN) has a ROC (Joel Greenblatt) % of -7,557.28% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #1168 out of 1322 companies in the Biotechnology industry, placing it in the top 88.4%.
Is Avalyn Pharma's ROC (Joel Greenblatt) % too high?
Avalyn Pharma's current ROC (Joel Greenblatt) % is -7,557.28%. Based on the distribution chart, Avalyn Pharma ranks #1168 out of 1322 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's ROC (Joel Greenblatt) % compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #1168 out of 1322 companies for ROC (Joel Greenblatt) %. This places Avalyn Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Avalyn Pharma and its competitors. Avalyn Pharma's current ROC (Joel Greenblatt) % is -7,557.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current ROC (Joel Greenblatt) % of -7,557.28%. The current ROC (Joel Greenblatt) % is -7,557.28%. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current ROC (Joel Greenblatt) % is -7,557.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avalyn Pharma Business Description

Address 105 W First Street, Boston, MA, USA, 02127
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score

Get the complete analysis for AVLN

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.50
Price